A phase I trial evaluating safety and pharmacokinetic of Metablok

Trial Profile

A phase I trial evaluating safety and pharmacokinetic of Metablok

Planning
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Metablok (Primary)
  • Indications Acute kidney injury; Cancer metastases; Sepsis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 16 Oct 2017 New trial record
    • 10 Oct 2017 According to a Arch Biopartners media release, the company is planning to file an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top